Table 1. Baseline characteristics of the patients enrolled in the study and according to the presence of subjective neuropathic symptoms.
| Characteristic | Total (n=136) | Symptoma (n=48) | No symptomb (n=88) | P value |
|---|---|---|---|---|
| Male sex | 68 (50.0) | 18 (37.5) | 50 (56.8) | 0.048 |
| Age, yr | 59.4±12.2 | 59.9±11.6 | 59.2±12.5 | 0.751 |
| Duration of T2DM, yr | 10.5±9.3 | 11.6±9.9 | 9.9±8.9 | 0.306 |
| HbA1c, % | 8.0±2.0 | 8.1±1.7 | 7.9±2.1 | 0.639 |
| eGFRc, mL/min/1.73 m2 | 90.09±11.87 | 89.38±11.81 | 90.49±11.95 | 0.605 |
| Hypertensiond | 85 (62.5) | 33 (68.8) | 52 (59.1) | 0.177 |
| Dyslipidemiae | 51 (37.5) | 21 (43.8) | 30 (34.1) | 0.177 |
| Vascular diseasef | 20 (14.7) | 9 (18.8) | 11 (12.5) | 0.230 |
| Mode of treatment | 0.252 | |||
| OADg | 113 (83.1) | 38 (79.2) | 75 (85.2) | |
| OAD+insulinh | 23 (16.9) | 10 (20.8) | 13 (14.8) |
Values are presented as number (%) or mean±standard deviation.
T2DM, type 2 diabetes mellitus; HbA1c, glycosylated hemoglobin; eGFR, estimated glomerular filtration rate; OAD, oral anti-diabetic drug.
aPatients had subjective neuropathic symptoms, bPatients had no subjective neuropathic symptoms, ceGFR is estimated GFR calculated by the Modification of Diet in Renal Disease equation, dHypertension was defined if any of the following criteria were met; use of antihypertensive medication, systolic blood pressure ≥140 mm Hg, or diastolic blood pressure ≥90 mm Hg, eDyslipidemia was defined if any of the following criteria were met; use of a lipid-lowering medication or plasma total cholesterol ≥240 mg/dL, fVascular disease was defined if any of the following criteria were met; cardiovascular disease, stroke and cerebrovascular disease or peripheral artery disease, gPatients were treated with one or more OADs, hPatients were treated with a combination of one or more OADs and insulin.